MehmetAsimBilenMD

Oncology • Atlanta, GA

Genitourinary Oncology

Director of Genitourinary Medical Oncology, Winship Cancer Institute of Emory University

Join to view full profile

Dr. Bilen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Bilen's full profile

Already have an account?

Office
Winship Cancer Institute Of Emory University
Atlanta, GA 30322
Phone+1 404-778-3460
Is this information wrong?

Summary

I serve as Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. I joined the clinical staff at Winship Cancer Institute as a practicing physician in July 2016. I am actively involved in clinical research and patient care in the area of genitourinary cancers, and serve as the Associate Medical Director of the Phase I Unit at Winship Cancer Institute. I work closely with the Fellowship Program of the Department of Hematology and Medical Oncology by educating fellows on genitourinary oncology. I also serve on the Winship Clinical and Translational Review Committee and Grady Clinical Research Committee.
I hold professional memberships with American Association for Cancer Research and American Society of Clinical Oncology.

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
Baylor College of MedicineResidency, Internal Medicine, 2010 - 2013
Hacettepe University FOMClass of 2008

Certifications & Licensure

GA State Medical License 2016 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) Start of enrollment: 2014 Nov 25
Active, not recruiting
Phase 1
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. Start of enrollment: 2015 Oct 14
Completed
Phase 1, Phase 2
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Start of enrollment: 2016 Mar 23
Active, not recruiting
Phase 3
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer Start of enrollment: 2016 Nov 30
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) Start of enrollment: 2017 Jan 12
Completed
Phase 2
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors Start of enrollment: 2016 Dec 19
Completed
Phase 1, Phase 2
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2018 Feb 22
Completed
Phase 2
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer Start of enrollment: 2019 Aug 06
Active, not recruiting
Phase 2
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer Start of enrollment: 2021 Jul 23
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohor...
Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mark Stein, Jeffrey Sosman, Robert Alter, David J Peace, David Einstein, Paul J Catalano, Meredith M Regan, Michael ...> ;Journal for Immunotherapy of Cancer. 2024 Apr 11
Cytoreductive surgery, systemic treatment, genetic evaluation, and patient perspective in a young adult with metastatic renal cell carcinoma.
Ahmet Yildirim, Swapnil Sheth, Edouard H Nicaise, Ellen Richter, Mani A Daneshmand, Shishir K Maithel, Kenneth Ogan, Mehmet A Bilen, Viraj A Master> ;CA. 2024 Apr 3
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
Joseph J Park, Alec Chu, Jinju Li, Alicia Ali, Rana R McKay, Clara Hwang, Matthew K Labriola, Albert Jang, Deepak Kilari, George Mo, Deepak Ravindranathan, Laura S Gra...> ;JCO Precision Oncology. 2024 Apr 1
Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis.
Jimmy S Patel, Yena Woo, Amber Draper, Caroline S Jansen, Pasquale F Innominato, Francis A Lévi, Layla Dhabaan, Haydn Kissick, Jennifer W Carlisle, Viraj A Master, Meh...> ;Journal for Immunotherapy of Cancer. 2024 Mar 26
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.
Nicholas A Zorko, Allison Makovec, Andrew Elliott, Samuel Kellen, John R Lozada, Ali T Arafa, Martin Felices, Madison Shackelford, Pedro Barata, Yousef Zakharia, Vivek...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 28
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
Park, J., Zengin, Z., Henderson, N., Park, J., Ali, A., Nguyen, C., Hwang, C., Barata, P., Bilen, M., Graham, L., Mo, G., Kilari, D., Tripathi, A., Labriola, M., Roths...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 22
Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches.
Chukkalore, D., MacDougall, K., Master, V., Bilen, M., Nazha, B.> ;The Oncologist. 2024 Feb 21
The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study.
Castellano, C., Sun, T., Ravindranathan, D., Hwang, C., Balanchivadze, N., Singh, S., Griffiths, E., Puzanov, I., Ruiz-Garcia, E., Vilar-Compte, D., Cárdenas-Delgado, ...> ;Cancer. 2024 Feb 20
Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy.
Nicaise, E., Schmeusser, B., Ali, A., Midenberg, E., Palacios, A., Hartsoe, B., Kearns, E., Ambadi, S., Patil, D., Joshi, S., Narayan, V., Psutka, S., Nazha, B., Brown...> ;Clinical Genitourinary Cancer. 2024 Feb 16
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.
Tanya Dorff, Lisa G Horvath, Karen Autio, Alice Bernard-Tessier, Matthew B Rettig, Jean-Pascal Machiels, Mehmet A Bilen, Martijn P Lolkema, Nabil Adra, Sylvie Rottey, ...> ;Clinical Cancer Research. 2024 Apr 15
Established and emerging biomarkers of immunotherapy in renal cell carcinoma.
Jani, Y., Jansen, C., Gerke, M., Bilen, M.> ;Immunotherapy. 2024 Apr 1
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
Miller, E., Eric J Miller, Tracy L Rose, Benjamin L Maughan, Matthew I Milowsky, Mehmet A Bilen, Bradley C Carthon, Xin Gao, Suthee Rapisuwon, Qianqian Zhao, Menggang ...> ;Cancer. 2024 May 1
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sanda, G., Shabto, J., Goyal, S., Liu, Y., Martini, D., Nazha, B., Brown, J., Yantorni, L., Anne Russler, G., Caulfield, S., Joshi, S., Narayan, V., Kissick, H., Ogan,...> ;The Oncologist. 2023 Dec 11
1 citations
The Genomic Landscape of Urothelial Carcinoma with High and LowExpression.
Krause, H., Elliott, A., Barata, P., Saleh, M., McKay, R., Hadadi, A., Brown, J., Nazha, B., Harik, L., Carthon, B., Miron, B., Nabhan, C., Yang, Y., Bilen, M.> ;Cancers. 2023 Dec 6
Prostate Cancer Skeletal Metastasis: A Spontaneous Evolution from Osteolytic to Osteoblastic Morphology without Treatment.
Lawal, I., Bilen, M., Halkar, R., Jani, A., Schuster, D.> ;World Journal of Nuclear Medicine. 2023 Dec 1
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R Merchan, Rana R McKay, Daniel...> ;Future Oncology. 2024 Mar 1
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study.
Gayathri Nagaraj, Shaveta Vinayak, Ali Raza Khaki, Tianyi Sun, Nicole M Kuderer, David M Aboulafia, Jared D Acoba, Joy Awosika, Ziad Bakouny, Nicole B Balmaceda, Ting ...> ;Elife. 2023 Oct 17
2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race.
Benjamin N Schmeusser, Dattatraya H Patil, Edouard H Nicaise, Manuel Armas-Phan, Reza Nabavizadeh, Vikram M Narayan, Shreyas S Joshi, Kenneth Ogan, Adeboye O Osunkoya,...> ;Cancer. 2024 Feb 1
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
Park, J., Holland, B., Jang, A., Clara Hwang, Nicholas C Henderson, Shih-Chun Chu, Brandon Holland, Frank C Cackowski, Amanda Pilling, Albert Jang, Shoshana Rothstein,...> ;JAMA Network Open. 2023 Sep 5
8 citations
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Bassel Nazha, Tony Zhuang, Sharon Wu, Jacqueline T Brown, Daniel Magee, Bradley C Carthon, Omer Kucuk, Chadi Nabhan, Pedro C Barata, Elisabeth I Heath, Charles J Ryan,...> ;Cancer. 2023 Dec 15
Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration.
Tanya Dorff, Zeynep Zengin, Nicholas Henderson, Alicia Ali, Charles Nguyen, Clara Hwang, Pedro C Barata, Mehmet Bilen, Laura Graham, George Mo, Deepak Kilari, Abhishek...> ;Research Square. 2023 Aug 10
Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker.
Benjamin N Schmeusser, Adil A Ali, Dattatraya H Patil, Eric Midenberg, Talia Helman, Manuel Armas-Phan, Reza Nabavizadeh, Shreyas S Joshi, Vikram M Narayan, Mehmet A B...> ;The Oncologist. 2023 Dec 11
1 citations
Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
Mehmet A Bilen, Scott B Robinson, Amy Schroeder, Jing Peng, Ruth Kim, Frank X Liu, Abhijeet Bhanegaonkar> ;The Oncologist. 2023 Sep 7
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.
Chloe S Lalonde, Jeffrey M Switchenko, Madhusmita Behera, Mehmet A Bilen, Taofeek K Owonikoko, Jonathan L Kaufman, Ajay K Nooka, Colleen M Lewis, Elise Hitron, Hannah ...> ;The Oncologist. 2023 Dec 11
16 citations
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, Christopher J Hoimes, Thomas W Flaig, Nataliya Mar, Helen H Moon, Terence W Friedlander, Rana R McKay, Mehmet...> ;Journal of Clinical Oncology. 2023 Sep 1
Join now to see all

Journal Articles

The Addition of Chemotherapy in the Definitive Management of High Risk Prostate Cancer
Bradley C Carthon, Mehmet A Bilen, Omer Kucuk, Urologic Oncology

Authored Content

Cabozantinib for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Retrospective AnalysisNovember 2018
The Addition of Chemotherapy in the Definitive Management of High Risk Prostate CancerOctober 2018

Press Mentions

Cancer Clinical Trials Are a Win for Patients, Doctors & ResearchersJuly 5th, 2022
Risky Business: A New Scoring System for Metastatic Renal Cell CarcinomaFebruary 11th, 2020
Debating the True Benefit of Adjuvant TKIs in High-Risk RCCOctober 4th, 2017
Join now to see all

Grant Support

Osteocrines in Therapy Resistance of Prostate Cancer Bone Metastasis: Evaluation of Strategies to Overcome Therapy Resistance from Tumor-Educated Bone Environment.Special Challenge Award - Prostate Cancer Foundation-JanssenPresent